Gina R Kruse1, Sara Kalkhoran2, Nancy A Rigotti2. 1. Division of General Internal Medicine, Tobacco Research and Treatment Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts;; Harvard Medical School, Boston, Massachusetts. Electronic address: gkruse@mgh.harvard.edu. 2. Division of General Internal Medicine, Tobacco Research and Treatment Center, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts;; Harvard Medical School, Boston, Massachusetts.
Abstract
INTRODUCTION: Electronic cigarette (e-cigarette) use is rising in the U.S. Smokers with comorbidities may increasingly use e-cigarettes if they believe e-cigarettes reduce smoking-related harm. This study examined e-cigarette use among adults with medical comorbidities. METHODS: In 2016, this study analyzed 68,136 U.S. adults in the 2014 and 2015 National Health Interview Survey. Prevalent e-cigarette use by medical comorbidities and adjusted odds of e-cigarette use were calculated. RESULTS: Among current cigarette smokers, ever use of e-cigarettes was more often reported by adults with one or more medical comorbidity versus those without comorbidity (18-24 years: 73.5% vs 61.4%; 25-44 years: 60.6% vs 54.3%; 45-64 years: 46.5% vs 40.3%; ≥65 years: 35.2% vs 19.4%; all p<0.05). Current smokers aged 25-64 years with one or more comorbidity reported current e-cigarette use more often than those without comorbidity (25-44 years, 17.8% vs 14.3%, p=0.03; 45-64 years, 15.9% vs 11.5%, p=0.02). Current smokers with chronic obstructive pulmonary disease, asthma, and cardiovascular disease had higher odds of ever e-cigarette use versus those without comorbidity. Current smokers with asthma and cardiovascular disease had higher odds of current e-cigarette use. Former smokers with chronic obstructive pulmonary disease had higher odds of ever and current e-cigarette use and former smokers with cancer had lower odds of current e-cigarette use. CONCLUSIONS: E-cigarette use by current and former smokers with medical comorbidities is substantial, especially among individuals with chronic lung or cardiovascular disease. Clinicians should routinely ask these patients about e-cigarette use, actively consider all pathways to help their patients quit combustible cigarettes, and recommend evidence-based treatments.
INTRODUCTION: Electronic cigarette (e-cigarette) use is rising in the U.S. Smokers with comorbidities may increasingly use e-cigarettes if they believe e-cigarettes reduce smoking-related harm. This study examined e-cigarette use among adults with medical comorbidities. METHODS: In 2016, this study analyzed 68,136 U.S. adults in the 2014 and 2015 National Health Interview Survey. Prevalent e-cigarette use by medical comorbidities and adjusted odds of e-cigarette use were calculated. RESULTS: Among current cigarette smokers, ever use of e-cigarettes was more often reported by adults with one or more medical comorbidity versus those without comorbidity (18-24 years: 73.5% vs 61.4%; 25-44 years: 60.6% vs 54.3%; 45-64 years: 46.5% vs 40.3%; ≥65 years: 35.2% vs 19.4%; all p<0.05). Current smokers aged 25-64 years with one or more comorbidity reported current e-cigarette use more often than those without comorbidity (25-44 years, 17.8% vs 14.3%, p=0.03; 45-64 years, 15.9% vs 11.5%, p=0.02). Current smokers with chronic obstructive pulmonary disease, asthma, and cardiovascular disease had higher odds of ever e-cigarette use versus those without comorbidity. Current smokers with asthma and cardiovascular disease had higher odds of current e-cigarette use. Former smokers with chronic obstructive pulmonary disease had higher odds of ever and current e-cigarette use and former smokers with cancer had lower odds of current e-cigarette use. CONCLUSIONS: E-cigarette use by current and former smokers with medical comorbidities is substantial, especially among individuals with chronic lung or cardiovascular disease. Clinicians should routinely ask these patients about e-cigarette use, actively consider all pathways to help their patients quit combustible cigarettes, and recommend evidence-based treatments.
Authors: Lila J Finney Rutten; Kelly D Blake; Amenah A Agunwamba; Rachel A Grana; Patrick M Wilson; Jon O Ebbert; Janet Okamoto; Scott J Leischow Journal: Nicotine Tob Res Date: 2015-01-14 Impact factor: 4.244
Authors: Ramzi G Salloum; Kayla R Getz; Andy S L Tan; Lisa Carter-Harris; Kelly C Young-Wolff; Thomas J George; Elizabeth A Shenkman Journal: Am J Prev Med Date: 2016-05-27 Impact factor: 5.043
Authors: Scott R Weaver; Ban A Majeed; Terry F Pechacek; Amy L Nyman; Kyle R Gregory; Michael P Eriksen Journal: Int J Public Health Date: 2015-11-12 Impact factor: 3.380
Authors: Sara Kalkhoran; Nicholas Alvarado; Maya Vijayaraghavan; Paula J Lum; Patrick Yuan; Jason M Satterfield Journal: J Gen Intern Med Date: 2017-07-14 Impact factor: 5.128
Authors: Yael R Symes; Kurt M Ribisl; Marcella H Boynton; J Lee Westmaas; Deborah K Mayer; Shelley D Golden Journal: J Cancer Surviv Date: 2019-01-24 Impact factor: 4.442
Authors: Natacha M De Genna; Thomas Ylioja; Anna E Schulze; Christine Manta; Antoine B Douaihy; Esa M Davis Journal: J Addict Med Date: 2017 Nov/Dec Impact factor: 3.702
Authors: Lisa M Fucito; Krysten W Bold; Stephen R Baldassarri; John P LaVigne; Bennie Ford; Polly Sather; Stephanie S O'Malley; Benjamin A Toll Journal: Prev Med Rep Date: 2021-06-09